These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 26572786)

  • 1. Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study.
    Carvalhal A; Gill MJ; Letendre SL; Rachlis A; Bekele T; Raboud J; Burchell A; Rourke SB;
    J Neurovirol; 2016 Jun; 22(3):349-57. PubMed ID: 26572786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility.
    Fabbiani M; Grima P; Milanini B; Mondi A; Baldonero E; Ciccarelli N; Cauda R; Silveri MC; De Luca A; Di Giambenedetto S
    Antivir Ther; 2015; 20(4):441-7. PubMed ID: 25516553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.
    Smurzynski M; Wu K; Letendre S; Robertson K; Bosch RJ; Clifford DB; Evans S; Collier AC; Taylor M; Ellis R
    AIDS; 2011 Jan; 25(3):357-65. PubMed ID: 21124201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-associated neurocognitive disorders and central nervous system drug penetration: what next?
    Marra CM
    Antivir Ther; 2015; 20(4):365-7. PubMed ID: 25781980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
    Sacktor N
    J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.
    Ellis RJ; Badiee J; Vaida F; Letendre S; Heaton RK; Clifford D; Collier AC; Gelman B; McArthur J; Morgello S; McCutchan JA; Grant I;
    AIDS; 2011 Sep; 25(14):1747-51. PubMed ID: 21750419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).
    Ndhlovu LC; Umaki T; Chew GM; Chow DC; Agsalda M; Kallianpur KJ; Paul R; Zhang G; Ho E; Hanks N; Nakamoto B; Shiramizu BT; Shikuma CM
    J Neurovirol; 2014 Dec; 20(6):571-82. PubMed ID: 25227930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV-infected adults?
    McManus H; Li PC; Nolan D; Bloch M; Kiertiburanakul S; Choi JY; Mulhall B; Petoumenos K; Zhou J; Law M; Brew BJ; Wright E
    HIV Med; 2011 Nov; 12(10):610-9. PubMed ID: 21819527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.
    Vassallo M; Fabre R; Durant J; Lebrun-Frenay C; Joly H; Ticchioni M; DeSalvador F; Harvey-Langton A; Dunais B; Laffon M; Cottalorda J; Dellamonica P; Pradier C
    J Neurovirol; 2017 Apr; 23(2):216-225. PubMed ID: 27815816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions.
    Caniglia EC; Cain LE; Justice A; Tate J; Logan R; Sabin C; Winston A; van Sighem A; Miro JM; Podzamczer D; Olson A; Arribas JR; Moreno S; Meyer L; del Romero J; Dabis F; Bucher HC; Wandeler G; Vourli G; Skoutelis A; Lanoy E; Gasnault J; Costagliola D; Hernán MA;
    Neurology; 2014 Jul; 83(2):134-41. PubMed ID: 24907236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent trends in early stage response to combination antiretroviral therapy in Australia.
    McManus H; Hoy JF; Woolley I; Boyd MA; Kelly MD; Mulhall B; Roth NJ; Petoumenos K; Law MG;
    Antivir Ther; 2015; 20(2):131-9. PubMed ID: 24704818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study.
    van den Dries LWJ; Wagener MN; Jiskoot LC; Visser M; Robertson KR; Adriani KS; van Gorp ECM
    AIDS Patient Care STDS; 2017 Aug; 31(8):329-334. PubMed ID: 28753395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.
    Yuan NY; Kaul M
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):90-112. PubMed ID: 31385157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.
    Arentoft A; Troxell K; Alvarez K; Aghvinian M; Rivera Mindt M; Cherner M; Van Dyk K; Razani J; Roxas M; Gavilanes M
    Viruses; 2022 May; 14(6):. PubMed ID: 35746623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid interferon alpha levels correlate with neurocognitive impairment in ambulatory HIV-Infected individuals.
    Anderson AM; Lennox JL; Mulligan MM; Loring DW; Zetterberg H; Blennow K; Kessing C; Koneru R; Easley K; Tyor WR
    J Neurovirol; 2017 Feb; 23(1):106-112. PubMed ID: 27400930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive Impairment in the Combined Antiretroviral Therapy Era in a Romanian Cohort of Young Adults with Chronic HIV Infection.
    Temereanca A; Ene L; Rosca A; Diaconu CC; Luca A; Burlacu R; Radoi R; Bulacu-Talnariu A; Marcotte TD; Achim CL; Ruta S
    AIDS Res Hum Retroviruses; 2020 May; 36(5):367-372. PubMed ID: 31476875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients.
    Ances BM; Roc AC; Korczykowski M; Wolf RL; Kolson DL
    J Neurovirol; 2008 Oct; 14(5):418-24. PubMed ID: 19040188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The far-reaching HAND of cART: cART effects on astrocytes.
    Gonzalez H; Podany A; Al-Harthi L; Wallace J
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):144-158. PubMed ID: 32147775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.